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Abstract: Biologically interesting bis-heterocycles bearing pyrazoline and 
imidazole moieties have been synthesized. 1H NMR, 13C NMR, IR and 
elemental analyses characterized the newly synthesized compounds. All the 
synthesized compounds were evaluated for their antimicrobial activity and 
were compared with the standard drugs. All the compounds demonstrated 
potent to weak antimicrobial activity. 
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Introduction 
The development of simple, facile and efficient synthetic methods for the synthesis of five 
membered heterocycles from readily available reagents is one of the major challenges in 
organic synthesis. Among five membered heterocycles, pyrazoline and imidazole are 
represents a class of compounds of great importance in biological chemistry. For instance, 
pyrazoline derivatives posses the biological activities like, antidepressant1, anticonvulsant2 
antimicrobial3, analgesic4 and antitumour5 activity and also serves as human acyl-CoA: 
cholesterol acyltransferase inhibitors.6 In fact, celecoxib a pyrazole derivative is now widely 
used in the market as anti-inflammatory drug.7 Imidazole derivatives are gaining synthetic 
interest in recent years due to their broad spectrum of biological activities like anti-
inflammatory8, analgesic9, antibacterial10, antifungal11, antituberculosis12, anticonvolusant13 
and potential anticytokine agents14. 2-n-Butyl-4-chloro-5-farmyl-imidazole is a key 
intermediate for the synthesis of Losartan a nonpeptide angiotensin antagonist, which is an 
orally active antihypertensive drug15. Literature studies reveals that bis-heterocycles bearing 
pyrazoline16,17 were synthesized via 1,3-dipolar cycloaddition of aldehyde hydrazone to 
divinyl ketone / sulfone using chloramine-T (CAT) as dehydrating agent.  
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     1,3-Dipolar cycloaddition reactions are useful tools for constructing biologically potent 
five membered heterocycles18. Apart from the various dipolar reagents known, nitrile imines 
are used in numerous 1,3-dipolar cycloaddition reactions leading to pyrazoles, pyrazolines, 
pyrazolidines and other heterocyclic compounds19. Huisgen and co-workers20 first reported 
the authentic in situ generation of nitrile imines by the thermolysis of 2,5-diphenyl tetrazole 
in the presence of ethyl phenylpropionate and obtained 2,3,5-triphenyl carbethoxypyrazole. 
Nitrile imines can be generated by photolysis of sydnones21 and oxidation of aryl aldehyde 
hydrazones with lead tetraacetate22, chloramine-T23 etc. In our laboratory Rai et al 
extensively used chloramine-T for the generation of nitrile oxide and nitrile imine from 
aldoxime and aldehyde hydrazones respectively. With this background, it is considered 
worthwhile to prepare bis-heterocycles using 1,3-dipolar cycloaddition reaction of 2-n-butyl-
4-chloro-(N-substituted)–imidazole substituted nitrile imine with different olefins  and 
screen them for antimicrobial activity. The present communication deals with the synthesis 
of bis-heterocycles via 1,3-dipolar cycloaddition reactions and their antimicrobial activity.  
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Experimental 
1H NMR spectra were recorded on a Bruker AM 300 MHz spectrometer using CDCl3 as 
solvent and tetramethylsilane as internal standard.13C NMR spectra were measured on Jeol 
400 (100MHz) instrument. The chemical shifts are expressed in δ and following 
abbreviations were used: s = singlet, d = doublet, t = triplet and m = multiplet. Infrared (IR) 
spectra were measured on Shimadzu 8300 spectrometer. Elemental analyses were obtained 
on a Vaio-EL intrument. Thinlayer chromatography (TLC) was done with pre-coated silica 
gel G plates using benzene-ethylacetrate as eluent. 
Antimicrobial activity 
All the synthesized compounds were evaluated for antimicrobial activity by the disc 
diffusion method26 and microdilution method27. Five bacteria and  five  fungal  species  were  
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used as the antimicrobial test strains namely: Bacillus substilis, Escherichia coli, 
Pseudomonas fluorescens, Xanthomonas campestris pvs, Xanthomonas oryzae, Aspergillus 
niger, Aspergillus flavus, Fusarium oxysporium, Trichoderma species, Fusarium and 
monaliforme. Streptomycin and tetracycline were used as standard drugs against bacteria and 
nystatin was used against fungi. In all the determinations tests were performed in triplicate 
and the results were taken as a mean of at least three determinations. 
Preparation of 4’-(2-Butyl-4-chloro-5-formyl-imidazol-1-ylmethyl)-2-carbonitrile (2) 
A mixture of 2-butyl-5-chloro-3H-imidazole-4-carbaldehyde (1.0 g, 5.37 mmol) and anhyd. 
K2CO3 (0.90 g, 6.52 mmol) in dimethylformamide (15 mL) were stirred for 15 min at room 
temperature.  4’-Bromomethyl-biphenyl-2-carbonitrile (1.45 g, 5.33 mmol) was then added and 
the mixture was stirred at room temperature for 6 h. After completion of the reaction (TLC 
toluene-ethylacetate; 7:3) the reaction mass was diluted with 25 mL water and the product was 
extracted with dichloromethane (25 mL). The extract was washed with water (10 mL) and then 
dried (Na2SO4). The solvent was evaporated and the remaining pale yellow oil was crystallized 
from ethanol to give 2 as a white crystalline solid (1.81 g 89%), mp 108-110 oC. 
Synthesis of 4,5-dihydro-3-(substituted-imidazole)-1,5-diphenyl-1H-pyrazoline (5a)  
A mixture of 3 (1.0 g, 2.13 mmol), 4a (0.23 g, 2.2 mmol) and chloramine-T trihydrate (0.6 g, 2.13 
mmol) in ethanol (20 mL) was warmed on a water bath for 2-3 h. TLC monitored the progress of 
the reaction. After completion of the reaction the solvent was evaporated in vacuum. The residual 
mass was extracted into ether (25 mL), washed successively with water (2 x 20 mL), 5% NaOH  
(1 x 10 mL), brine solution (2 x 15 mL) and dried over anhydrous sodium sulphate. Evaporation of 
the solvent afforded crude oily substance, which was purified by column chromatography using 
benzene-ethylacetate (8:1) as eluent to give the product as thick oil (0.75 g, 62%).   
4,5-dihydro-3-(substituted-imidazole)-5-methyl-1,5-diphenyl-1H-pyrazoline (5b) 
Obtained from 3 (1.0 g, 2.13 mmol), 4b (0.25 g, 2.12 mmol) and chloramine-T trihydrate 
(0.6 g, 2.13 mmol) as thick oil (0.88 g, 70%).  
4,5-dihydro-3-(substituted-imidazole)-1-phenyl-1H-pyrazoline-5-carbonitrile (5c)  
Obtained from 3 (1.0 g, 2.13 mmol), 4c (0.12 g, 2.20 mmol) and chloramine-T trihydrate 
(0.6 g, 2.13 mmol) as thick oil (0.7 g, 63%).  
5-(Chloromethyl)-4,5-dihydro-3-(substituted-imidazole)-1-phenyl-1H-pyrazoline (5d) 
Obtained from 3 (1.0 g, 2.13 mmol), 4d (0.17 g, 2.23 mmol) and chloramine-T trihydrate 
(0.6 g, 2.13 mmol) as thick oil (0.73 g, 63%).  
5-(bromomethyl)-4,5-dihydro-3-(substituted-imidazole)-1-phenyl-1H-pyrazoline (5e)  
Obtained from 3 (1.0 g, 2.13 mmol), 4e (0.26 g, 2.14 mmol) and chloramine-T trihydrate 
(0.6 g, 2.13 mmol) as thick oil (0.82 g, 66%).  
4,5-dihydro-3-(substituted-imidazole)-1-phenyl-1H-pyrazol-yl)methanol (5f) 
Obtained from 3 (1.0 g, 2.13 mmol), 4f (0.125 g, 2.15 mmol) and chloramine-T trihydrate 
(0.6 g, 2.13 mmol) as thick oil (0.68 g, 61%). 
4,5-dihydro-3-(substituted-imidazole)-1-phenyl-1H-pyrazol-5-yl acetate (5g)  
Obtained from 3 (1.0 g, 2.13 mmol), 4g (0.185 g, 2.15 mmol) and chloramine-T trihydrate 
(0.6 g, 2.13 mmol) as thick oil (0.91 g, 77 %).  
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4,5-dihydro-3-(substituted-imidazole)-1-phenyl-1H-pyrazol-5-yl propionate (5h) 
Obtained from 3 (1.0 g, 2.13 mmol), 4h (0.215 g, 2.15 mmol) and chloramine-T trihydrate 
(0.6 g, 2.13 mmol) as thick oil (0.92 g, 76%).  
Results and Discussion 
The general synthetic pathway discussed hereafter is depicted in the Scheme. Compound 1 
was alkylated using 4’-Bromomethyl-biphenyl-2-carbonitrile and potassium carbonate in 
DMF. Then farmyl function of 2 was converted into the phenylhydrazone 3. When oxidative 
dehydrogenation of 3 by chloramine-T (CAT) afforded nitrile imine, which was in situ 
trapped by the different olefins 4 (a-h) under refluxing condition in ethanol. Thus produced 
compound was identified by NMR spectroscopy and elemental analyses as 4,5-dihydro-3-
(substituted imidazole)-5-substituted-1-phenyl-1H-pyrazoline 5 (a-h) in good quality and 
yield. The starting substrate 2-n-butyl-4-chloro-(N-substituted)–imidazole-5-carbaldehyde 1 
was prepared according to literature procedure24. Imidazole aldehyde phenylhydrazone was 
prepared by known procedure25. 
Antimicrobial activity 
Antimicrobial activity of all the compounds was shown in Table 1 and 2. Among the series 
of synthesized compounds, 5d and 5e shown better inhibition. Remaining compounds shown 
moderate inhibition. The better inhibition shown by 5d and 5e may be due to the presence of 
chloro and bromo group in the compound.   
Table 1. Minimal inhibitory concentration in µg mL-1[X] and Inhibitory zone in (diameter) 
mm [Y] of the synthesized compounds against tested bacterial strains by micro dilution 
method and disk diffusion method respectively 
Bacillus 
substilis 
Escherichia 
coli 
Pseudomonas 
fluorescens 
Xanthomonas 
campestris  pvs 
Xanthomonas 
oryzae Compound 
X Y 
 mm
X Y  
mm 
X Y 
mm 
X Y 
mm 
X Y 
 mm 
5a 21 07 26 13 23 16 25 12 23 12 
5b 22 10 21 11 25 14 22 11 24 11 
5c 19 13 17 14 20 17 19 14 23 12 
5d 17 14 12 13 13 15 10 10 11 10 
5e 18 11 14 11 12 16 12 11 14 12 
5f 25 07 22 09 28 13 27 10 23 11 
5g 22 10 22 10 26 11 23 11 24 12 
5h 24 09 22 09 29 15 25 12 23 10 
Streptomycin 19 13 13 14 12 17 - - - - 
Tetracycline - - -  09 12 13 12 
Streptomycin sulfate (25 µg per disc); Tetracycline (25 µg per disc) were used as positive 
reference standard antibactierial discs, Synthesized compounds (25 µg per disc). 
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Table 2. Minimal inhibitory concentration in µg mL-1[X] and Inhibitory zone in (diameter) 
mm [Y] of the synthesized compounds against tested fungal strains by micro dilution 
method and disk diffusion method respectively 
Aspergillus
 niger 
Aspergillus 
 flavus 
Fusarium 
oxysporium
Trichoderma 
species 
Fusarium 
monalifome 
 
Compound X Y 
mm 
X Y  
mm 
X Y 
mm 
X Y 
mm 
X Y 
mm 
5a    18 08 18 09 14 12 15 14 14 11 
5b    18 07 18 07 18 11 17 12 15 09 
5c    16 08 16 10 13 13 14 15 11 11 
5d    14 09 13 12 10 16 11 17 10 14 
5e    15 09 15 11 11 14 13 16 10 12 
5f    19 07 19 07 17 11 17 12 15 09 
5g    21 07 26 08 23 15 25 12 23 12 
5h    22 08 21 10 25 14 22 11 24 11 
Nystatin 15 08 15 10 11 14 12 16             09 12 
Nystatin (25 µg per disc) was used as positive reference standard antifungal discs, 
synthesized compounds (25 µg per disc).                                     
Spectral analysis of compounds    
Compound 2: 1H NMR CDCl3: δ 0.92 (t, 3H, CH3), 1.34 (m, 2H, CH2), 1,66 (m, 2H, CH2), 2.57 (t, 
2H, CH2), 4.96 (s, 2H, CH2), 7.12-7.36 (m, 4H, ArH), 7.5-7.65 (m, 4H, ArH), 9.62 (s, 1H, CH), 13C 
NMR CDCl3: δ 14.2 (C), 23.4 (C), 23.9 (C), 34.8 (C), 42.4 (C), 114.6 (C), 118.5 (C), 127.4 (2C), 
128.2 (2C), 129.6 (2C), 132.1 (C), 133.2 (C), 133.4 (C), 136.1 (C), 136.9 (C), 140.9 (C), 142.9 (C), 
161.7 (C), 189.1 (C). IR (KBr pellets cm-1) v 3070, .2996, 2241, 1762, 1667, 1576, 1299. Anal. 
Calcd. For C22H20ClN3O: C, 69.93, H, 5.33, N, 11.12%. Found: C, 69.99, H, 5.38, N11.09%.  
Compound 5a: 1H NMR CDCl3: δ 0.94 (t, 3H, CH3), 1.34 (m, 2H, CH2), 1,66 (m, 2H, CH2), 2.57 
(t, 2H, CH2), 3.34 (dd, J=6.2, 1H, 4-H), 3.42 (dd, 1H, J=6.2, 4-H), 5.17 (dd, 1H, J=2.0, 5-H), 5.02 
(s, 2H, CH2), 6.62-7.10 (m, 5H, ArH), 7.18-7.37 (m, 4H, ArH), 7.42-7.65 (m, 4H, ArH), 13C NMR 
CDCl3: δ 14.1 (C), 23.1 (C), 26.7 (C), 33.2 (C), 39.5 (C), 53.2 (C), 104.7 (C), 113.5 (2C), 115.9 (C), 
117.7 (C), 122.2 (C), 126.3 (C), 126.8 (C), 127.2 (2C), 127.8 (2C), 128.4 (C), 128.7 (4C), 129.7 
(4C), 132.9 (C), 133.8 (2C), 135.4 (C), 142.7 (C), 143.4 (C), 143.8 (C), 148.6 (C), 156.1 (C). 
Anal.Calcd. For C36H32ClN5; C, 75.84; H, 5.66; N, 12.28; Found: C, 75.85, H, 5.67, N, 12.28  
Compound 5b: 1H NMR CDCl3: δ 0.96 (t, 3H, CH3), 1.36 (m, 2H, CH2), 1.62 (s, 3H, CH3), 1.65 
(m, 2H, CH2), 2.58 (t, 2H, CH2), 3.32 (s, 2H, 4-CH2), 5.10 (s, 2H, CH2), 6.64-7.06 (m, 6H, ArH), 
7.13-7.19 (m, 6H, ArH), 7.38-7.68 (m, 6H, ArH). 13C NMR CDCl3: δ 14.2 (C), 23.2 (C), 26.8 
(C), 30.1 (C), 33.4 (C), 41.4 (C), 47.3 (C), 56.2 (C), 104.6 (C), 113.5 (2C), 115.9 (C), 117.8 (C), 
122.2 (C), 126.2 (C), 126.2 (C), 126.6 (2C), 127.7 (2C), 128.4 (3C), 128.7 (C), 129.9 (4C), 132.9 
(C), 133.4 (C), 133.8 (C), 135.4 (C), 142.7 (C), 143.8 (C), 144.4 (C), 148.3 (C), 156.3 (C). 
Anal.Calcd. For C37H34ClN5; C, 76.08; H, 5.87; N, 11.99; Found: C, 76.10, H, 5.86, N, 11.98%.  
Compound 5c: 1H NMR CDCl3: δ 0.94 (t, 3H, CH3), 1.33 (m, 2H, CH2), 1,64 (m, 2H, CH2), 
2.55 (t, 2H, CH2), 3.37 (dd, 1H, J=6.0, 4-H), 3.40 (dd, 1H, J=6.0, 4-H), 5.19 (dd, 1H, J=3.6, 5-
H), 5.00 (s, 2H, CH2), 6.60-7.08 (m, 5H, ArH), 7.16-7.32 (m, 4H, ArH), 7.40-7.65 (m, 4H, ArH), 
13C NMR CDCl3: δ 14.2 (C), 23.0 (C), 25.7 (C), 32.6 (C), 33.5 (C), 40.8 (C), 41.1 (C), 104.7 (C), 
113.7 (2C), 115.9 (C), 116.6 (C), 117.8 (C), 122.3 (C), 126.3 (C), 127.9 (2C), 128.5 (C), 128.8(C), 
314 K.M. LOKANATHA RAI et al. 
129.7 (4C), 132.8 (C) 133.6 (2C), 135.4 (C), 142.7 (C), 144.0 (C), 148.5 (C), 156.7 (C). 
Anal.Calcd. For C31H27ClN6; C, 71.73; H, 5.24; N, 16.19. Found: C, 71.73; H, 5.23; N, 16.19 %. 
Compound 5d: 1H NMR CDCl3: δ 0.98 (t, 3H, CH3), 1.35 (m, 2H, CH2), 1,66 (m, 2H, CH2), 
2.57 (t, 2H, CH2), 3.32 (dd, 1H, J=6.4, 4-H), 3.37 (dd, 1H, J=6.4, 4-H), 3.46 (dd, 1H, J=4.0, 
CH2Cl), 3.70 (dd, 1H, J=4.0, CH2Cl), 4.98 (s, 2H, CH2), 5.10 (m, 1H, 5-H), 6.58-7.08 (m, 
5H, ArH), 7.16-7.38 (m, 4H, ArH), 7.42-7.65 (m, 4H, ArH), 13C NMR CDCl3: δ 14.2 (C), 
22.8 (C), 26.0 (C), 33.2 (C), 34.6 (C), 40.7 (C), 52.4 (C), 53.4 (C), 104.7 (C), 113.6 (2C), 
116.0 (C), 117.5 (C), 122.2 (C), 126.3 (C), 127.8 (2C), 128.4 (C), 128.8 (C), 129.7 (4C), 
132.4 (C), 133.5 (2C), 135.4 (C), 142.5 (C), 144.0 (C), 148.4 (C), 156.4 (C). Anal.Calcd. 
For C31H29Cl2N5; C, 68.63; H, 5.39; N, 12.91. Found: C, 68.64; H, 5.38; N, 12.93 %. 
Compound 5e: 1H NMR CDCl3: δ 0.95 (t, 3H, CH3), 1.32 (m, 2H, CH2), 1,63 (m, 2H, CH2), 
2.54 (t, 2H, CH2), 3.30 (dd, 1H, J=6.6, 4-H), 3.35 (dd, 1H, J=6.6,  4-H), 3.42 (dd, 1H, J=3.2, 
CH2Br), 3.68 (dd, 1H, J=3.2, CH2Br), 5.16 (m, 1H, 5-H), 4.98 (s, 2H, CH2), 6.50-7.08 (m, 5H, 
ArH), 7.12-7.36 (m, 4H, ArH), 7.42-7.65 (m, 4H, ArH), 13C NMR CDCl3: δ 14.2 (C), 22.6 (C), 
26.0 (C), 33.2 (C), 35.9 (C), 36.6 (C), 39.2 (C), 40.5 (C), 54.4 (C), 104.7 (C), 113.6 (2C), 
116.0 (C), 117.4 (C), 122.0 (C), 126.2 (C), 127.8 (2C), 128.4 (C), 128.7 (C), 129.7 (4C), 132.5 
(C), 133.5 (C), 135.4 (C), 142.6 (C), 143.8 (C), 148.2 (C), 155.4 (C). Anal.Calcd. For 
C31H29BrClN5; C, 63.43; H, 4.98; N, 11.93. Found: C, 63.45, H, 4.98, N, 11.91 %. 
Compound 5f: 1H NMR CDCl3: δ 0.96 (t, 3H, CH3), 1.33 (m, 2H, CH2), 1,63 (m, 2H, CH2), 2.56 
(t, 2H, CH2), 3.24 (dd, 1H, J=6.2, 4-H), 3.30 (dd, 1H, J=6.2, 4-H), 3.61-3.86 (m, 2H, CH2), 5.02 (s, 
2H, CH2), 5.17 (m, 1H, 5-H), 6.52-7.10 (m, 5H, ArH), 7.16-7.37 (m, 4H, ArH), 7.42-7.65 (m, 4H, 
ArH). 13C NMR CDCl3: δ 14.3 (C), 23.1 (C), 26.0 (C), 33.2 (C), 33.7 (C), 40.9 (C), 53.1 (C), 66.4 
(C), 104.5 (C), 113.5 (2C), 115.8 (C), 117.2 (C), 122.2 (C), 126.7 (C), 127.7 (2C), 128.5 (C), 128.9 
(C), 129.7 (4C), 132.8 (C), 133.3 (C), 133.8 (C), 135.4 (C), 142.6 (C), 144.0 (C), 148.4 (C), 156.5 
(C). Anal.Calcd. For C31H30ClN5O; C, 71.05; H, 5.77; N, 13.36; Found: C, 69.99, H, 6.13, N, 13.03. 
Compound 5g: 1H NMR CDCl3: δ 0.94 (t, 3H, CH3), 1.33 (m, 2H, CH2), 1,66 (m, 2H, CH2), 
2.02 (s, 3H, CH3), 2.55 (t, 2H, CH2), 3.37 (dd, 1H, J=6.0, 4-H), 3.42 (dd, 1H, J=6.0, 4-H), 
5.42 (dd, 1H, J=4.0, 5-H), 5.04 (s, 2H, CH2), 6.57-7.06 (m, 5H, ArH), 7.15 (d, 2H), 7.37 (d, 
2H, ArH), 7.42-7.67 (m, 4H, ArH), 13C NMR CDCl3: δ 14.3 (C), 20.8 (C), 23.3 (C), 26.7 
(C), 33.5 (C), 37.2 (C), 40.6 (C), 78.4 (C), 104.7 (C), 113.6 (2C), 115.9 (C), 117.3 (C), 
122.1 (C), 126.6 (C), 127.8 (2C), 128.4 (C), 128.8 (C), 129.6 (4C), 132.7 (C), 133.5 (C), 
133.8 (C), 135.4 (C), 142.7 (C), 144.1 (C), 148.3 (C), 155.9 (C), 170.5 (C). Anal.Calcd. For 
C32H30ClN5O2 C, 69.62; H, 5.48; N, 12.69; Found: C, 69.62, H, 5.46, N, 12.70 %. 
Compound 5h: 1H NMR CDCl3: δ 0.96 (t, 3H, CH3), 1.14 (t, 3H, CH3), 1.34 (m, 2H, CH2), 1,66 
(m, 2H, CH2), 2.32 (q, 2H, CH2), 2.57 (t, 2H, CH2), 3.34 (dd, 1H, J=6.4, 4-H), 3.42 (dd, 1H, 
J=6.4, 4-H), 5.38 (dd, 1H, J=4.0, 5-H), 5.02 (s, 2H, CH2), 6.52-7.05 (m, 5H, ArH), 7.14-7.37 (m, 
4H, ArH), 7.40-7.66 (m, 4H, ArH), 13C NMR CDCl3: δ 10.1 (C), 14.1 (C), 22.9 (C), 25.7 (C), 
27.6 (C), 33.7 (C), 37.5 (C), 40.7 (C), 50.1 (C), 78.9 (C), 104.7 (C), 113.6 (2C), 115.8 (C), 117.7 
(C), 122.3 (C), 126.7 (C), 127.8 (2C), 128.4 (C), 128.7 (C), 129.7 (4C), 132.8 (C), 133.5 (C), 
135.4 (C), 142.7 (C), 144.0 (C), 148.4 (C), 156.8 (C), 173.2 (C). Anal.Calcd. For C33H32ClN5O2; 
C, 70.02; H, 5.70; N, 12.37; Found: C, 70.04, H, 5.70, N, 12.38 %. 
Conclusion 
In conclusion 4, 5- dihydro -3- (substituted - imidazole) – 5 - substituted-1-phenyl-1H-pyrazoline 
derivatives were synthesized and their antimicrobial activity have been evaluated. Compounds 5d  
and 5e shows significant inhibition, remaining compounds demonstrated potent to moderate 
antimicrobial activity. Further research in this area is under progress in our laboratory. 
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